Objectives: This manuscript describes the development of PTT (Partial Thromboplastin Time) Advisor, one of the first of a handful of iOS-based mobile applications to be released by the US Centers for Disease Control and Prevention (CDC). PTT Advisor has been a collaboration between two groups at CDC (Informatics R&D and Laboratory Science), and one partner team (Clinical Laboratory Integration into Healthcare Collaborative - CLIHC). The application offers clinicians a resource to quickly select the appropriate follow-up tests to evaluate patients with a prolonged PTT and a normal Prothrombin Time (PT) laboratory result.
Methods: The application was designed leveraging an agile methodology, and best practices in user experience (UX) design and mobile application development.
Results: As it is an open-source project, the code to PTT Advisor was made available to the public under the Apache Software License. On July 6, 2012, the free app was approved by Apple, and was published to their App Store.
Conclusions: Regardless of the complexity of the mobile application, the level of effort required in the development process should not be underestimated. There are several issues that make designing the UI for a mobile phone challenging (not just small screen size): the touchscreen, users' mobile mindset (tasks need to be quick and focused), and the fact that mobile UI conventions/expectations are still being defined and refined (due to the maturity level of the field of mobile application development).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733759 | PMC |
| http://dx.doi.org/10.5210/ojphi.v5i2.4363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.
Radiother Oncol
January 2025
Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium. Electronic address:
Article Synopsis
- - There is a need for better tools to help manage oligometastatic castration-sensitive prostate cancer (omCSPC), as highlighted in a retrospective study examining the effectiveness of the ArteraAI Prostate Test.
- - This study involved 222 men and measured outcomes like overall survival (OS) and time until the cancer becomes castration-resistant, finding a high MMAI score linked to worse OS and shorter time to resistance.
- - Additionally, the study indicated that patients with high MMAI scores who received metastasis-directed therapy (MDT) had improved metastasis-free survival compared to those with low scores, pointing to the potential of the MMAI biomarker for guiding treatment decisions.
Molecular mechanisms of penile traction for penile rehabilitation in a bilateral cavernous nerve crush injury rat model.
Transl Androl Urol
August 2023
Department of Urology, School of Medicine, Tulane University, New Orleans, LA, USA.
Background: Prostate cancer is the most common solid-organ malignancy in adult men. Early detection and treatment of prostate cancer with radical prostatectomy (RP) has improved cancer-specific survival but is associated with penile shortening and erectile dysfunction. Penile traction therapy (PTT) has been demonstrated to increase stretched penile length (SPL) prior to penile prosthesis placement and may improve erectile function (EF) in patients with Peyronie's disease.
View Article and Find Full Text PDFBackground: Androgen deprivation therapy (ADT) with radiotherapy can benefit patients with localized prostate cancer. However, ADT can negatively impact quality of life and there remain no validated predictive models to guide its use.
Methods: Digital pathology image and clinical data from pre-treatment prostate tissue from 5,727 patients enrolled on five phase III randomized trials treated with radiotherapy +/- ADT were used to develop and validate an artificial intelligence (AI)-derived predictive model to assess ADT benefit with the primary endpoint of distant metastasis.
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
Commun Biol
November 2022
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Astatine-211-parthanatine ([At]PTT) is an alpha-emitting radiopharmaceutical therapeutic that targets poly(adenosine-diphosphate-ribose) polymerase 1 (PARP1) in cancer cells. High-risk neuroblastomas exhibit among the highest PARP1 expression across solid tumors. In this study, we evaluated the efficacy of [At]PTT using 11 patient-derived xenograft (PDX) mouse models of high-risk neuroblastoma, and assessed hematological and marrow toxicity in a CB57/BL6 healthy mouse model.
View Article and Find Full Text PDFProstate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
NPJ Digit Med
June 2022
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient's optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostication rely on non-specific and semi-quantitative tools, commonly leading to over- and under-treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!